Artiva R&D head granted RSUs and options
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.
Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.
Insider Trade Summary
Grant/Award: 310,000 shares
Grant/Award
2 txns
Insider
Miralles Gines Diego
Role
President & Head of R&D
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 232,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 77,500 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 232,500 contracts (Direct);
Common Stock — 77,500 shares (Direct)
Footnotes (3)
- F1. Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan.
- F2. Represents stock option award granted under the Issuer's 2025 Inducement Plan.
- F3. 25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months.
Key Figures
RSU grant: 77,500 shares
Option grant size: 232,500 options
Option exercise price: $9.22 per share
+4 more
7 metrics
RSU grant
77,500 shares
Restricted stock unit award under 2025 Inducement Plan
Option grant size
232,500 options
Employee stock option award linked to common stock
Option exercise price
$9.22 per share
Strike price for employee stock options
Common shares held
77,500 shares
Total common stock directly held after grants
Option holdings
232,500 options
Total options directly held after grants
Initial cliff vesting date
May 15, 2027
25% of option shares vest on this date
Option expiration
May 17, 2036
Expiration date of the employee stock options
Key Terms
restricted stock unit, Employee Stock Option (Right to Buy), 2025 Inducement Plan, exercise price, +1 more
5 terms
restricted stock unit financial
"Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Employee Stock Option (Right to Buy) financial
"Employee Stock Option (Right to Buy) with underlying common stock shares."
2025 Inducement Plan financial
"Award granted under the Issuer's 2025 Inducement Plan."
exercise price financial
"Employee stock options have a conversion or exercise price of 9.2200."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Artiva Biotherapeutics (ARTV) grant to Diego Miralles?
Artiva Biotherapeutics granted Diego Miralles 77,500 restricted stock units and 232,500 stock options. Both awards were made under the company’s 2025 Inducement Plan, aligning his compensation more closely with shareholder value through equity-based incentives and long-term vesting.
What is the exercise price of the new Artiva Biotherapeutics (ARTV) stock options?
The new employee stock options for Diego Miralles carry an exercise price of $9.22 per share. This price is the amount he must pay to purchase each share once the options vest and become exercisable according to their specified vesting schedule.
How do the Artiva Biotherapeutics (ARTV) stock options for Diego Miralles vest?
The options vest over time: 25% of the 232,500 option shares vest on May 15, 2027. The remaining 75% then vest in equal monthly installments, at 1/36th per month, across the following 36 months, encouraging long-term employment.
What is the 2025 Inducement Plan mentioned in the Artiva Biotherapeutics (ARTV) Form 4?
The 2025 Inducement Plan is the equity plan under which these awards were granted. It provides for restricted stock units and stock options as inducement compensation, helping Artiva Biotherapeutics attract and retain key employees with performance- and tenure-based equity incentives.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates